January 14, 2019 07:52 AM ESTUpdated 11:23 AM
Financing

Kalei­do, Cir­ius brace the IPO mar­ket seek­ing a com­bined $186M — de­spite bar­ri­ers at shut­down-mode SEC

Amber Tong

As biotech stocks cel­e­brate a post-JPM ral­ly around the best ever start to the year, Kalei­do Bio­sciences and Cir­ius Ther­a­peu­tics have ap­plied to join the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times